Latest Insider Transactions at Acceleron Pharma Inc (XLRN)
This section provides a real-time view of insider transactions for Acceleron Pharma Inc (XLRN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ACCELERON PHARMA INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ACCELERON PHARMA INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 29
2021
|
Thomas A Mccourt Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,622
+21.16%
|
-
|
|
Jan 29
2021
|
Karen L. Smith Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,622
+26.23%
|
-
|
|
Jan 29
2021
|
Joseph S Zakrzewski Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,622
+4.49%
|
-
|
|
Jan 29
2021
|
Habib J Dable CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
16,662
+14.47%
|
-
|
|
Jan 29
2021
|
Jay T. Backstrom EVP, Research and Development |
BUY
Grant, award, or other acquisition
|
Direct |
5,409
+20.65%
|
-
|
|
Jan 29
2021
|
Sujay Kango EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,409
+21.81%
|
-
|
|
Jan 29
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
4,868
+31.31%
|
-
|
|
Jan 29
2021
|
Adam M Veness SVP, General Counsel and Sec. |
BUY
Grant, award, or other acquisition
|
Direct |
4,868
+18.8%
|
-
|
|
Jan 05
2021
|
Habib J Dable CEO and President |
SELL
Open market or private sale
|
Direct |
4,258
-1.26%
|
$515,218
$121.77 P/Share
|
|
Jan 05
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
1,499
-5.51%
|
$182,878
$122.17 P/Share
|
|
Jan 05
2021
|
Adam M Veness SVP, General Counsel and Sec. |
SELL
Open market or private sale
|
Direct |
2,056
-3.8%
|
$252,888
$123.23 P/Share
|
|
Jan 04
2021
|
Habib J Dable CEO and President |
SELL
Payment of exercise price or tax liability
|
Direct |
3,278
-3.67%
|
$406,472
$124.31 P/Share
|
|
Jan 04
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
3,280
-5.97%
|
$406,720
$124.29 P/Share
|
|
Jan 04
2021
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
624
-5.56%
|
$77,376
$124.31 P/Share
|
|
Jan 04
2021
|
Jay T. Backstrom EVP, Research and Development |
SELL
Payment of exercise price or tax liability
|
Direct |
1,735
-10.14%
|
$215,140
$124.31 P/Share
|
|
Jan 04
2021
|
Sujay Kango EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-32.03%
|
$1,250,000
$125.07 P/Share
|
|
Jan 04
2021
|
Sujay Kango EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,357
-8.84%
|
$168,268
$124.31 P/Share
|
|
Jan 04
2021
|
Adam M Veness SVP, General Counsel and Sec. |
SELL
Payment of exercise price or tax liability
|
Direct |
942
-4.92%
|
$116,808
$124.31 P/Share
|
|
Dec 14
2020
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
42,528
-79.13%
|
$5,528,640
$130.14 P/Share
|
|
Dec 14
2020
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
42,528
+22.09%
|
$1,445,952
$34.99 P/Share
|
|
Dec 11
2020
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
3,100
-21.65%
|
$387,500
$125.0 P/Share
|
|
Dec 11
2020
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,100
+17.8%
|
$127,100
$41.2 P/Share
|
|
Dec 10
2020
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
500
-4.27%
|
$62,500
$125.12 P/Share
|
|
Dec 10
2020
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
500
+1.07%
|
$17,000
$34.99 P/Share
|
|
Dec 09
2020
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
SELL
Open market or private sale
|
Direct |
3,872
-25.66%
|
$484,000
$125.03 P/Share
|
|
Dec 09
2020
|
Kevin F Mclaughlin SVP, CFO and Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,872
+6.51%
|
$131,648
$34.99 P/Share
|
|
Oct 12
2020
|
Terrence C Kearney Director |
SELL
Open market or private sale
|
Direct |
37,500
-34.52%
|
$4,462,500
$119.32 P/Share
|
|
Oct 12
2020
|
Terrence C Kearney Director |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+27.15%
|
$1,050,000
$28.84 P/Share
|
|
Jul 09
2020
|
Celgene Corp /De/ > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,241
-0.03%
|
$228,582
$102.28 P/Share
|
|
Jul 09
2020
|
Celgene Corp /De/ > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
38,979
+0.55%
|
$194,895
$5.88 P/Share
|
|
Jul 01
2020
|
Celgene Corp /De/ > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
108,108
+1.53%
|
$9,945,936
$92.5 P/Share
|